SIB-1553A
SIB-1553A
SIB-1553A (/ˈsɪb-ˈfɪftiːn-ˈfɪftiː-ˈθriː-ˈeɪ/) is a pharmacological agent that is primarily used in the field of neuroscience for its potential therapeutic effects. The etymology of the term is derived from the abbreviation of the company that first synthesized it, SIB, and the unique identifier 1553A.
Pharmacology
SIB-1553A is a subtype-selective agonist that primarily targets nicotinic acetylcholine receptors (nAChRs). It exhibits a higher affinity for the β4 subunit-containing nAChRs compared to the α7 subunit-containing nAChRs. This selectivity is believed to be responsible for its potential therapeutic effects.
Therapeutic Use
SIB-1553A has been studied for its potential use in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is believed to improve cognitive function and reduce motor symptoms in animal models of these diseases.
Side Effects
As with any pharmacological agent, SIB-1553A may have potential side effects. However, due to its experimental nature, these side effects are not yet fully understood.
See Also
External links
- Medical encyclopedia article on SIB-1553A
- Wikipedia's article - SIB-1553A
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski